Cell News and Research

RSS

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Investigators to examine how Ephb2 gene causes ependymoma in children

Armed with new grant support, investigators at Nationwide Children's Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma.

2 Jun 2011

Study explains differences between male and female victims in community violence assaults

A new study from Rhode Island Hospital shows that a large proportion of victims of community violence treated in its emergency department are female. Injured adolescent females are more likely than males to be injured by a relative or intimate partner, and are more likely to be injured by a single assailant.

2 Jun 2011

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated.

2 Jun 2011

Researchers discover overactive genes that drive triple-negative breast cancer cells

Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.

2 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Adipose-derived stem cell procedure restores skull defects after brain surgery

Stem cells derived from abdominal fat—used along with a synthetic bone grafting material—are a potentially valuable new approach to repairing skull defects after brain surgery, according to a study in the June issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration.

1 Jun 2011

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Pfizer Inc. announced today that the European Medicines Agency has accepted Pfizer's filing for regulatory review of axitinib for patients with advanced renal cell carcinoma after failure of prior systemic treatment.

1 Jun 2011

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

1 Jun 2011

Elsevier to organise third Current Opinion conference in structural biology, DNA repair

Elsevier, the leading provider of scientific, technical and medical information products and services, is organising the third Current Opinion conference, the Current Opinion in Structural Biology & DNA Repair.

1 Jun 2011

Scientists find no link between XMRV retrovirus and human disease

Delineation of the origin of the retrovirus known as XMRV from the genomes of laboratory mice indicates that the virus is unlikely to be responsible for either prostate cancer or chronic fatigue syndrome in humans, as has been widely published.

1 Jun 2011

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company's lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago.

1 Jun 2011

CTI regains compliance with all applicable NASDAQ listing standards

Cell Therapeutics, Inc. announced that it has received a letter from The NASDAQ Stock Market LLC, indicating that CTI has regained compliance with the minimum bid price rule (i.e., NASDAQ Listing Rule 5550(a)(2)) for continued listing on The NASDAQ Capital Market and that CTI is in compliance with all applicable listing standards.

1 Jun 2011

Mouse virus not responsible for Chronic Fatigue Syndrome, new study finds

Two years ago, a widely publicized scientific report plucked an old mouse virus out of obscurity and held it up as a possible cause of Chronic Fatigue Syndrome. According to a new study published today by a group of researchers in California, Wisconsin and Illinois, that report was wrong.

1 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

MMRGlobal, VZJ to launch consumer and professional health IT products

MMRGlobal, Inc. and VisiInc PLC have entered into an agreement to launch MMRGlobal's patented consumer and professional health IT products and services, including MMRPro for healthcare professionals and the MyMedicalRecords Personal Health Record (PHR), on the Visi platform utilizing the Vistime product.

1 Jun 2011

Cell News and Research

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Investigators to examine how Ephb2 gene causes ependymoma in children

Study explains differences between male and female victims in community violence assaults

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Researchers discover overactive genes that drive triple-negative breast cancer cells

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Adipose-derived stem cell procedure restores skull defects after brain surgery

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Elsevier to organise third Current Opinion conference in structural biology, DNA repair

Scientists find no link between XMRV retrovirus and human disease

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

CTI regains compliance with all applicable NASDAQ listing standards

Mouse virus not responsible for Chronic Fatigue Syndrome, new study finds

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

MMRGlobal, VZJ to launch consumer and professional health IT products

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News